| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ETON Stock Overview
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases.
Eton Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.04 |
| 52 Week High | US$4.78 |
| 52 Week Low | US$1.95 |
| Beta | 1.44 |
| 1 Month Change | 21.12% |
| 3 Month Change | 33.83% |
| 1 Year Change | -24.57% |
| 3 Year Change | -49.59% |
| 5 Year Change | n/a |
| Change since IPO | -51.36% |
Recent News & Updates
Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous
Sep 13Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' Story
Aug 14Recent updates
Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher
Apr 15
Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely
Oct 14What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates
Aug 18Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner
May 15Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Apr 05Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?
Mar 01Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To Profit
Jan 07
Do Insiders Own Lots Of Shares In Eton Pharmaceuticals, Inc. (NASDAQ:ETON)?
Jul 06Shareholder Returns
| ETON | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.4% | 0.5% | -0.4% |
| 1Y | -24.6% | 13.2% | -20.6% |
Return vs Industry: ETON underperformed the US Pharmaceuticals industry which returned 13.2% over the past year.
Return vs Market: ETON underperformed the US Market which returned -20.6% over the past year.
Price Volatility
| ETON volatility | |
|---|---|
| ETON Average Weekly Movement | 9.9% |
| Pharmaceuticals Industry Average Movement | 11.1% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: ETON is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ETON's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 17 | Sean Brynjelsen | https://www.etonpharma.com |
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis.
Eton Pharmaceuticals, Inc. Fundamentals Summary
| ETON fundamental statistics | |
|---|---|
| Market Cap | US$76.90m |
| Earnings (TTM) | -US$8.89m |
| Revenue (TTM) | US$18.85m |
4.1x
P/S Ratio-8.6x
P/E RatioIs ETON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ETON income statement (TTM) | |
|---|---|
| Revenue | US$18.85m |
| Cost of Revenue | US$4.96m |
| Gross Profit | US$13.88m |
| Other Expenses | US$22.78m |
| Earnings | -US$8.89m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.35 |
| Gross Margin | 73.67% |
| Net Profit Margin | -47.19% |
| Debt/Equity Ratio | 57.1% |
How did ETON perform over the long term?
See historical performance and comparison